ArticleArchives of medical science : AMS2025
MiR-28-3p regulates high glucose-induced endothelial dysfunction by targeting CXXC5.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Putative Novel miR-1133 Is Associated with Oxidative Stress in Hyperglycemia-Induced Endothelial Cells.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Data from the CEO database show that microRNA (miR)-28-3p levels are elevated in diabetic patients. Nevertheless, the role of miR-28-3p in peripheral artery disease with diabetes has not been investigated. Material and methods: The levels of miR-28-3p, CXXC5, CXXC-type zinc finger protein 5, and CXXC5's downstream molecules as well as endothelial function were investigated. Dual luciferase analyses were used to confirm the binding site of miR-28-3p and CXXC5. Results: Under high-glucose conditions, miR-28-3p expression is upregulated, whereas CXXC5 expression is downregulated. Overexpression of miR-28-3p increased cell apoptosis and inhibited cell proliferation, migration, and vessel formation, whilst inhibiting its expression had the opposite effect. The overexpression and inhibition of miR-28-3p could also influence both the mRNA and protein levels of CXXC5 and its known downstream molecules. Analysis of bioinformatics data revealed a potential binding site for miR-28-3p and CXXC5. Dual luciferase analyses demonstrated that miR-28-3p suppressed CXXC5 expression by targeting the 3'-untranslated region (3'-UTR) of CXXC5. Following that, we overexpressed both miR-28-3p and CXXC5. The level of CXXC5 and its known downstream signaling molecules decreased with miR-28-3p overexpression alone. As anticipated, co-overexpression of miR-28-3p and CXXC5 partially reversed the effect of miR-28-3p mimics. Conclusions: These findings indicated that miR-28-3p regulated high glucose-induced endothelial dysfunction by targeting CXXC5.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.